Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis

Alla Mitrofanova, Judith Molina, Javier Varona Santos, Johanna Guzman, Ximena A. Morales, G. Michelle Ducasa, Jonathan Bryn, Alexis Sloan, Ion Volosenco, Jin Ju Kim, Mengyuan Ge, Shamroop K. Mallela, Matthias Kretzler, Sean Eddy, Sebastian Martini, Patricia Wahl, Santiago Pastori, Armando J. Mendez, George W. Burke, Sandra MerscherAlessia Fornoni

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Studies suggest that altered renal lipid metabolism plays a role in the pathogenesis of diabetic kidney disease and that genetic or pharmacological induction of cholesterol efflux protects from the development of diabetic kidney disease and focal segmental glomerulosclerosis (FSGS). Here we tested whether altered lipid metabolism contributes to renal failure in the Col4a3 knockout mouse model for Alport Syndrome. There was an eight-fold increase in the cholesterol content in renal cortexes of mice with Alport Syndrome. This was associated with increased glomerular lipid droplets and cholesterol crystals. Treatment of mice with Alport Syndrome with hydroxypropyl-β-cyclodextrin (HPβCD) reduced cholesterol content in the kidneys of mice with Alport Syndrome and protected from the development of albuminuria, renal failure, inflammation and tubulointerstitial fibrosis. Cholesterol efflux and trafficking-related genes were primarily affected in mice with Alport Syndrome and were differentially regulated in the kidney cortex and isolated glomeruli. HPβCD also protected from proteinuria and mesangial expansion in a second model of non-metabolic kidney disease, adriamycin-induced nephropathy. Consistent with our experimental findings, microarray analysis confirmed dysregulation of several lipid-related genes in glomeruli isolated from kidney biopsies of patients with primary FSGS enrolled in the NEPTUNE study. Thus, lipid dysmetabolism occurs in non-metabolic glomerular disorders such as Alport Syndrome and FSGS, and HPβCD improves renal function in experimental Alport Syndrome and FSGS.

Original languageEnglish (US)
Pages (from-to)1151-1159
Number of pages9
JournalKidney international
Volume94
Issue number6
DOIs
StatePublished - Dec 2018

Keywords

  • Alport syndrome
  • FSGS
  • cholesterol metabolism
  • hydroxypropyl beta cyclodextrin
  • renal function

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis'. Together they form a unique fingerprint.

  • Cite this

    Mitrofanova, A., Molina, J., Varona Santos, J., Guzman, J., Morales, X. A., Ducasa, G. M., Bryn, J., Sloan, A., Volosenco, I., Kim, J. J., Ge, M., Mallela, S. K., Kretzler, M., Eddy, S., Martini, S., Wahl, P., Pastori, S., Mendez, A. J., Burke, G. W., ... Fornoni, A. (2018). Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. Kidney international, 94(6), 1151-1159. https://doi.org/10.1016/j.kint.2018.06.031